Current Report Filing (8-k)
October 26 2020 - 8:05AM
Edgar (US Regulatory)
0001730430
false
0001730430
2020-10-23
2020-10-23
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
October 23, 2020
Kiniksa Pharmaceuticals, Ltd.
(Exact name of Registrant as Specified in
Its Charter)
Bermuda
|
|
001-730430
|
|
98-1327726
|
(State or other jurisdiction of
incorporation or organization)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
Kiniksa Pharmaceuticals, Ltd.
Clarendon House
2 Church Street
Hamilton HM11, Bermuda
(808) 451-3453
(Address, zip code and telephone number,
including area code of principal executive offices)
Kiniksa Pharmaceuticals Corp.
100 Hayden Avenue
Lexington, MA, 02421
(781) 431-9100
(Address, zip code and telephone number,
including area code of agent for service)
N/A
(Former Name or Former Address, if Changed
Since Last Report)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
|
o
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
o
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
o
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
o
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of
the Act:
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange on which
registered
|
Class A Common Shares $0.000273235 par value
|
|
KNSA
|
|
The Nasdaq Global Select Market
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of
the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company x
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 7.01. Regulation FD.
On October 26, 2020, Kiniksa Pharmaceuticals, Ltd.
(“Kiniksa”) announced data from the Phase 2 clinical trial of mavrilimumab in Giant Cell Arteritis
(“GCA”) included in the abstract entitled “Mavrilimumab (anti GM-CSF Receptor α Monoclonal Antibody)
Reduces Time to Flare and Increases Sustained Remission in a Phase 2 Trial of Patients with Giant Cell Arteritis” (the
“Abstract”) that was posted by The American College of Rheumatology (“ACR”) to ACR’s website.
Table 1 was inadvertently omitted during the online posting of the abstract. Table 1, as submitted to ACR by the authors for
publication and referenced in the abstract, is included in Kiniksa’s press release announcing the data. A copy of the
Press Release announcing such data is furnished with this Current Report on Form 8-K as Exhibit 99.1. A link to the
Abstract, inclusive of Table 2 only, follows:
https://acrabstracts.org/abstract/mavrilimumab-anti-gm-csf-receptor-%ce%b1-monoclonal-antibody-reduces-time-to-flare-and-increases-sustained-remission-in-a-phase-2-trial-of-patients-with-giant-cell-arteritis/
Kiniksa expects data from the global Phase 2 clinical trial
of mavrilimumab in GCA to be presented at the late-breaking abstracts session during the ACR Convergence 2020 by Dr. Maria
Cid of Hospital Clínic, University of Barcelona, IDIBAPS and co-principal investigator for the trial, in a virtual presentation
entitled “Mavrilimumab (anti GM-CSF receptor α monoclonal antibody) Reduces Time to Flare and Increases Sustained Remission
in a Phase 2 Trial of Patients with Giant Cell Arteritis” on Monday, November 9, 2020 at 11:30 a.m. Eastern Time.
Reference to the ACR website address does not constitute incorporation
by reference of the abstract or any other information contained at or available through the ACR website, and you should not consider
it to be a part of this Current Report on Form 8-K.
The information contained in this Item 7.01 of this Current
Report on Form 8-K and Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor
shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless
of any general incorporation language in such filing and except as expressly provided by specific reference in such filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
The
following exhibit 99.1 relates to Item 7.01, which shall be deemed to be furnished, and not filed:
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
KINIKSA PHARMACEUTICALS, LTD.
|
|
|
|
|
|
Date: October 26, 2020
|
By:
|
/s/ Thomas Beetham
|
|
|
Thomas Beetham
|
|
|
Executive Vice President, Chief Legal Officer
|
Kiniksa Pharmaceuticals (NASDAQ:KNSA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Kiniksa Pharmaceuticals (NASDAQ:KNSA)
Historical Stock Chart
From Sep 2023 to Sep 2024